| 제목 | Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors | ||
|---|---|---|---|
| 작성자 | 관리자 | 등록일 | 2022-07-13 |
내용
Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors
Sungkeun Shim 1 2, Danbee Kang 3 2, Nayeon Kim 3 4, Gayeon Han 2, Jihyun Lim 2, Hyunsoo Kim 1 2, Jeonghyun Park 3, Mankyung Lee 1 2, Jeong Eon Lee 5, Seok Won Kim 5, Jonghan Yu 5, Byung Joo Chae 5, Jai Min Ryu 5, Seok Jin Nam 5, Se Kyung Lee 5, Juhee Cho 3 2 4 6
Affiliations expand
- PMID: 34645130
- DOI: 10.4143/crt.2021.784
Free article
Full text linksCite
Abstract
Purpose: Little is known about the impact of financial toxicity in disease-free breast cancer survivors. We aim to validate the COST in Korean (COST-K) and evaluate financial toxicity among disease-free breast cancer survivors.
Materials and methods: We conducted linguistic validation following a standardized methodology recommended by FACITtrans. For psychometric validation, we conducted a cross-sectional survey with 4,297 disease-free breast cancer survivors at a tertiary hospital in Seoul, Korea between November 2018 and April 2019. Survivors were asked to complete the COST-K and EORTC QLQ-C30 questionnaires. The test-retest reliability, internal consistency, and validity of the COST-K were assessed using standard scale construction techniques.
Results: The COST-K demonstrated good internal consistency, with a Cronbach's α of 0.81. The test-retest analysis revealed an intraclass correlation coefficient of 0.78. The COST-K had moderate correlation (r = -0.60) with the financial difficulty item of the EORTC QLQ-C30 and week correlation with the items on acute and chronic symptom burdens (nausea/vomiting = -0.18, constipation = -0.14, diarrhea = -0.14), showing good convergent and divergent validity. The median COST-K was 27 (range, 0-44; mean ± SD, 27.1 ± 7.5) and about 30% and 5% of cancer survivors experienced mild and severe financial toxicity, respectively. Younger age, lower education, lower household income was associated with higher financial toxicity.
Conclusion: The COST-K is a valid and reliable instrument for measuring financial toxicity in disease-free breast cancer survivors. Considering its impact on the HRQOL, more studies need to be conducted to evaluate financial toxicity in cancer survivors and design interventions.
Keywords: Breast neoplasms; Cancer survivors; Financial toxicity; Quality of life; Validation study.
